KR101498834B1
(ko)
*
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
HUE026039T2
(en)
*
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
JP5757534B2
(ja)
|
2009-03-25 |
2015-07-29 |
ジェネンテック, インコーポレイテッド |
抗fgfr3抗体およびこれを用いた方法
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
JP6224739B2
(ja)
*
|
2013-03-15 |
2017-11-01 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
抗lag−3結合タンパク質
|
BR112015025347A2
(pt)
|
2013-04-09 |
2017-07-18 |
Boston Biomedical Inc |
2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
|
ES2728578T3
(es)
*
|
2013-09-20 |
2019-10-25 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
SG11201604738TA
(en)
|
2013-12-12 |
2016-07-28 |
Shanghai Hengrui Pharm Co Ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
EA201990240A1
(ru)
|
2013-12-24 |
2019-06-28 |
Бристол-Маерс Сквибб Компани |
Новые трициклические соединения в качестве противораковых средств
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
DK3556775T3
(da)
|
2014-01-28 |
2022-01-03 |
Bristol Myers Squibb Co |
Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CA2938193C
(en)
|
2014-01-31 |
2023-05-02 |
Aimm Therapeutics B.V. |
Means and methods for producing stable antibodies
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
NZ725006A
(en)
|
2014-03-12 |
2019-11-29 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
PT3116909T
(pt)
*
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
BR112016020333B1
(pt)
|
2014-03-24 |
2022-08-09 |
Novartis Ag |
Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA2951259A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
TWI693232B
(zh)
*
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
US10160726B2
(en)
|
2014-08-06 |
2018-12-25 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
JO3663B1
(ar)
*
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
BR112017006664A2
(pt)
|
2014-10-03 |
2017-12-26 |
Novartis Ag |
terapias de combinação
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TN2017000129A1
(en)
|
2014-10-14 |
2018-10-19 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-l1 and uses thereof
|
WO2016073738A2
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
EP3725808A1
(en)
|
2014-11-21 |
2020-10-21 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
WO2016094639A1
(en)
*
|
2014-12-10 |
2016-06-16 |
Wisconsin Alumni Research Foundation |
Mini-intronic plasmid dna vaccines in combination with lag3 blockade
|
RS59507B1
(sr)
|
2014-12-16 |
2019-12-31 |
Novartis Ag |
Jedinjenja izoksazol hidroksamske kiseline kao inhibitori lpxc
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
BR112017013385A2
(pt)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos para tigit
|
US11116838B2
(en)
|
2015-01-29 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
|
MA41463A
(fr)
*
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
US20160243228A1
(en)
*
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
ES2789331T3
(es)
|
2015-03-02 |
2020-10-26 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
CN107530415A
(zh)
|
2015-03-10 |
2018-01-02 |
艾杜罗生物科技公司 |
用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
|
BR112017021021A2
(pt)
|
2015-04-03 |
2018-07-03 |
Bristol-Myers Squibb Company |
inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
|
RS61531B1
(sr)
|
2015-04-13 |
2021-04-29 |
Five Prime Therapeutics Inc |
Kombinovana terapija za kancer
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
CA2988126A1
(en)
|
2015-06-03 |
2016-12-08 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
EA039293B1
(ru)
*
|
2015-06-05 |
2021-12-30 |
Мерк Шарп И Доум Корп. |
Антитела против lag3 и антигенсвязывающие фрагменты
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
CN115887671A
(zh)
|
2015-07-16 |
2023-04-04 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
CN114853891A
(zh)
*
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
EP3328419B1
(en)
|
2015-07-30 |
2021-08-25 |
MacroGenics, Inc. |
Pd-1-binding molecules and methods of use thereof
|
KR20180042370A
(ko)
|
2015-08-25 |
2018-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
AU2016316730B2
(en)
|
2015-09-02 |
2023-05-25 |
Immutep S.A.S. |
Anti-LAG-3 Antibodies
|
WO2017058115A1
(en)
*
|
2015-09-29 |
2017-04-06 |
Asia Biotech Pte. Ltd. |
Pd-1 antibodies and uses thereof
|
KR102146319B1
(ko)
|
2015-10-02 |
2020-08-25 |
에프. 호프만-라 로슈 아게 |
Pd1 및 tim3에 특이적인 이중특이성 항체
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
WO2017083224A1
(en)
|
2015-11-09 |
2017-05-18 |
Bristol-Myers Squibb Company |
Methods to manipulate quality attributes of polypeptides produced in cho cells
|
JP6945456B2
(ja)
*
|
2015-11-13 |
2021-10-06 |
マクロジェニクス,インコーポレーテッド |
Lag‐3結合分子及びその使用方法
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
US11213586B2
(en)
|
2015-11-19 |
2022-01-04 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
|
RS61866B1
(sr)
*
|
2015-11-20 |
2021-06-30 |
Regeneron Pharma |
Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3
|
AU2016359609B2
(en)
|
2015-11-23 |
2023-12-07 |
Five Prime Therapeutics, Inc. |
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
EP3390406A1
(en)
|
2015-12-15 |
2018-10-24 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
AU2016371639A1
(en)
|
2015-12-16 |
2018-06-28 |
Merck Sharp & Dohme Llc |
Anti-LAG3 antibodies and antigen-binding fragments
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
EP3402819A1
(en)
|
2016-01-11 |
2018-11-21 |
Novartis AG |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
UY37128A
(es)
|
2016-02-19 |
2017-09-29 |
Novartis Ag |
Compuestos tetracíclicos de piridona como antivirales
|
EP3423489A1
(en)
*
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
PL3433257T3
(pl)
|
2016-03-24 |
2024-02-12 |
Novartis Ag |
Analogi nukleozydów alkinylu jako inhibitory ludzkiego rinowirusa
|
CN109789195A
(zh)
|
2016-04-13 |
2019-05-21 |
维维雅生物技术公司 |
离体bite激活的t细胞
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
JP2019516682A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
CN109415320A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
JP2019519485A
(ja)
|
2016-05-04 |
2019-07-11 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11066383B2
(en)
|
2016-05-04 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
BR112018072986A2
(pt)
|
2016-05-18 |
2019-03-06 |
Boehringer Ingelheim International Gmbh |
anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
|
RS62935B1
(sr)
|
2016-05-20 |
2022-03-31 |
Biohaven Therapeutics Ltd |
Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
MA45250B1
(fr)
|
2016-06-14 |
2020-09-30 |
Novartis Ag |
Forme crystalline de (r)-4-(5-(cyclopropyléthynyl)isoxazol-3-yl)-n-hydroxy-2-méthyl-2-(méthylsulfonyl)butanamide en tant qu'agent antibacteriel
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
PT3472207T
(pt)
|
2016-06-20 |
2021-03-31 |
F Star Delta Ltd |
Moléculas ligantes que se ligam a pd-l1 e lag-3
|
KR20190022632A
(ko)
|
2016-06-20 |
2019-03-06 |
에프-스타 베타 리미티드 |
Lag-3 결합 구성원
|
MX2018016364A
(es)
|
2016-06-20 |
2019-11-28 |
Kymab Ltd |
Anticuerpos anti-pd-l1.
|
JP6998895B2
(ja)
|
2016-06-23 |
2022-01-18 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Lag-3抗体、その抗原結合フラグメント、およびそれらの医薬的用途
|
MX2018016227A
(es)
|
2016-06-24 |
2019-07-08 |
Infinity Pharmaceuticals Inc |
Terapias de combinacion.
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
AU2017297603A1
(en)
|
2016-07-14 |
2019-02-14 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
AU2017313496B2
(en)
*
|
2016-08-15 |
2023-09-21 |
Fuso Pharmaceutical Industries, Ltd. |
Anti-LAG-3 antibody
|
EP3503916A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
JP7274413B2
(ja)
|
2016-09-23 |
2023-05-16 |
マレンゴ・セラピューティクス,インコーポレーテッド |
ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
WO2018069500A2
(en)
*
|
2016-10-13 |
2018-04-19 |
Symphogen A/S |
Anti-lag-3 antibodies and compositions
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
BR112019011651A2
(pt)
|
2016-12-07 |
2020-01-07 |
Agenus Inc. |
Anticorpos anti-cttla-4 e métodos de uso dos mesmos
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
EP4310082A3
(en)
|
2017-01-20 |
2024-04-10 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
EP3580238A1
(en)
|
2017-02-10 |
2019-12-18 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
CA3053989A1
(en)
|
2017-02-22 |
2018-08-30 |
I-Mab |
Anti-lag-3 antibodies and uses thereof
|
KR20190133213A
(ko)
|
2017-03-31 |
2019-12-02 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
US20200031944A1
(en)
|
2017-03-31 |
2020-01-30 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
PE20191494A1
(es)
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
MA49042A
(fr)
|
2017-04-05 |
2020-02-12 |
Symphogen As |
Polythérapies ciblant pd-1, tim-3 et lag-3
|
MA49034B1
(fr)
|
2017-04-05 |
2022-09-30 |
Hoffmann La Roche |
Anticorps anti-lag3
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
EP3612563A1
(en)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
SG11201909710XA
(en)
|
2017-04-21 |
2019-11-28 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
WO2018200430A1
(en)
|
2017-04-26 |
2018-11-01 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
CA3059468A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
EP3628070B1
(en)
|
2017-04-28 |
2021-09-08 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides for use in increasing central memory t cells
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
WO2018208868A1
(en)
*
|
2017-05-10 |
2018-11-15 |
Smet Pharmaceutical Inc |
Human monoclonal antibodies against lag3 and uses thereof
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN110891974B
(zh)
|
2017-05-12 |
2021-08-06 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
CN110636846B
(zh)
|
2017-05-17 |
2023-05-16 |
艾库斯生物科学有限公司 |
用于治疗癌症相关疾病的喹唑啉吡唑衍生物
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
EP3630179A2
(en)
*
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
CA3060984A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
AU2018275109A1
(en)
|
2017-06-01 |
2020-01-02 |
Xencor, Inc. |
Bispecific antibodies that bind CD 123 CD3
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのIL−1β結合性抗体
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
JP2020526520A
(ja)
|
2017-06-30 |
2020-08-31 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ido阻害剤の非晶質形体および結晶形体
|
EP3652212A4
(en)
*
|
2017-07-13 |
2021-04-14 |
Nanjing Leads Biolabs Co., Ltd. |
LAG-3 BINDING ANTIBODIES AND USES THEREOF
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
KR20200032180A
(ko)
|
2017-07-28 |
2020-03-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
JP7269917B2
(ja)
|
2017-08-17 |
2023-05-09 |
イケナ オンコロジー, インコーポレイテッド |
Ahr阻害剤およびその使用
|
SG11202001441WA
(en)
|
2017-08-18 |
2020-03-30 |
Tragara Pharmaceuticals Inc |
Polymorphic form of tg02
|
WO2019046225A1
(en)
|
2017-08-30 |
2019-03-07 |
Phanes Therapeutics, Inc. |
ANTI-LAG-3 ANTIBODIES AND USES THEREOF
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
CN111032672A
(zh)
|
2017-08-31 |
2020-04-17 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11623932B2
(en)
|
2017-09-22 |
2023-04-11 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US20200262917A1
(en)
*
|
2017-10-05 |
2020-08-20 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
CN111344297B
(zh)
|
2017-10-10 |
2023-10-20 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍処置法
|
KR20200065065A
(ko)
|
2017-10-16 |
2020-06-08 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
US20210189336A1
(en)
|
2017-10-18 |
2021-06-24 |
Vivia Biotech, S.L. |
Bite-activated car-t cells
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
Hpk1阻害剤として有用なイソフラノン化合物
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
CN111315749A
(zh)
|
2017-11-17 |
2020-06-19 |
诺华股份有限公司 |
新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
WO2019121906A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Specific pd-l1 binding sequences inserted in a ch3 domain
|
CN111433210A
(zh)
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
KR20200104314A
(ko)
|
2017-12-22 |
2020-09-03 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
Lag-3 항체 약학 조성물 및 이의 용도
|
WO2019133531A1
(en)
|
2017-12-26 |
2019-07-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN111788227A
(zh)
|
2017-12-27 |
2020-10-16 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
CN109970856B
(zh)
*
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
CN111542546B
(zh)
*
|
2018-01-18 |
2022-08-16 |
四川科伦博泰生物医药股份有限公司 |
抗lag-3抗体及其用途
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
JP7250808B2
(ja)
|
2018-03-08 |
2023-04-03 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3768720A4
(en)
*
|
2018-03-20 |
2022-01-05 |
Wuxi Biologics Ireland Limited |
NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
CN111886256A
(zh)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
抗mica和/或micb抗体及其用途
|
CN111971306A
(zh)
|
2018-03-30 |
2020-11-20 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
CN110343178B
(zh)
*
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
抗人lag-3单克隆抗体及其应用
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
US20190365861A1
(en)
|
2018-04-18 |
2019-12-05 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CA3102256A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
CN112384531A
(zh)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
CN110606892B
(zh)
*
|
2018-06-14 |
2023-09-26 |
华博生物医药技术(上海)有限公司 |
一种高亲和力高生物活性的lag-3抗体及其应用
|
CN110615840A
(zh)
*
|
2018-06-19 |
2019-12-27 |
信达生物制药(苏州)有限公司 |
全人源的抗lag-3抗体及其应用
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
JP7373512B2
(ja)
|
2018-06-27 |
2023-11-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用なナフチリジノン化合物
|
CN112654621A
(zh)
|
2018-06-27 |
2021-04-13 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|
US11945864B2
(en)
|
2018-06-29 |
2024-04-02 |
Y-Biologics Inc. |
Monoclonal antibody specifically binding to LAG-3 and use thereof
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
JP7411627B2
(ja)
|
2018-07-09 |
2024-01-11 |
ファイヴ プライム セラピューティクス インク |
Ilt4と結合する抗体
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
JP2021532143A
(ja)
*
|
2018-07-26 |
2021-11-25 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の処置のためのlag−3併用療法
|
CN110172099B
(zh)
*
|
2018-08-16 |
2020-03-03 |
上海健信生物医药科技有限公司 |
抗lag-3人源化单克隆抗体分子,抗原结合片段及其医药用途
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20220089587A1
(en)
|
2018-09-07 |
2022-03-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2020053654A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
JP2022500002A
(ja)
|
2018-09-21 |
2022-01-04 |
イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド |
新規インターロイキン2およびその使用
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
JP2022504839A
(ja)
|
2018-10-10 |
2022-01-13 |
ティロス・セラピューティクス・インコーポレイテッド |
抗lap抗体変異体及びその使用
|
WO2020077276A2
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
MX2021003903A
(es)
*
|
2018-10-19 |
2021-06-04 |
Bristol Myers Squibb Co |
Terapia combinada para el melanoma.
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
EP3880708A1
(en)
|
2018-11-16 |
2021-09-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
KR20210109564A
(ko)
|
2018-12-21 |
2021-09-06 |
옹쎄오 |
신규의 컨쥬게이티드 핵산 분자 및 이의 용도
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN111620949A
(zh)
|
2019-02-28 |
2020-09-04 |
三生国健药业(上海)股份有限公司 |
结合人lag-3的抗体、其制备方法和用途
|
EA202192555A1
(ru)
|
2019-03-19 |
2021-11-25 |
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн |
Комбинированная терапия для лечения рака
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
JP2022519923A
(ja)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
EP3946619A1
(en)
|
2019-03-26 |
2022-02-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of stat3
|
EP3947403A1
(en)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
CN113939300A
(zh)
|
2019-04-05 |
2022-01-14 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
MX2021013815A
(es)
|
2019-05-13 |
2021-12-14 |
Regeneron Pharma |
Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
|
US20230242478A1
(en)
|
2019-05-13 |
2023-08-03 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
WO2020252353A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
AU2020291936A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
EP3991747A4
(en)
*
|
2019-06-24 |
2023-07-05 |
Innovent Biologics (Suzhou) Co., Ltd. |
PREPARATIONS WITH ANTI-LAG-3 ANTIBODIES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
|
MX2022000164A
(es)
|
2019-07-03 |
2022-04-01 |
Sumitomo Pharma Oncology Inc |
Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
|
IT201900011676A1
(it)
|
2019-07-12 |
2021-01-12 |
St Superiore Di Sanita |
Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici.
|
TWI819225B
(zh)
|
2019-07-16 |
2023-10-21 |
美國密西根州立大學 |
作為eed抑制劑之咪唑并嘧啶及其用途
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2021041664A1
(en)
|
2019-08-27 |
2021-03-04 |
The Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CA3155010A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The Universtiy Of Michigan |
Spirocyclic androgen receptor protein degraders
|
TW202124448A
(zh)
|
2019-09-19 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
於酸性pH結合VISTA之抗體
|
CN114450028A
(zh)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Lag-3拮抗剂治疗的定量空间剖析
|
AR120045A1
(es)
|
2019-09-26 |
2022-01-26 |
Novartis Ag |
Compuestos antivirales de pirazolopiridinona
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
WO2021072277A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
WO2021090146A1
(en)
|
2019-11-04 |
2021-05-14 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
MX2022005474A
(es)
|
2019-11-08 |
2022-06-02 |
Bristol Myers Squibb Co |
Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
|
AR120481A1
(es)
|
2019-11-19 |
2022-02-16 |
Bristol Myers Squibb Co |
Compuestos útiles como inhibidores de la proteína helios
|
US11591339B2
(en)
|
2019-11-26 |
2023-02-28 |
Ikena Oncology, Inc. |
Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
|
KR20220104794A
(ko)
|
2019-11-26 |
2022-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
(r)-n-(4-클로로페닐)-2-((1s,4s)-4-(6-플루오로퀴놀린-4-일)시클로헥실)프로판아미드의 염/공결정
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
IL294148A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted quinazolinyl compounds are useful as t-cell activators
|
JP2023508375A
(ja)
|
2019-12-23 |
2023-03-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換ピペラジン誘導体
|
JP2023508055A
(ja)
|
2019-12-23 |
2023-02-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
WO2021133752A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
WO2021141907A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hong Kong) Limited |
Anti-tnfr2 antibody and uses thereof
|
JP2023510429A
(ja)
|
2020-01-07 |
2023-03-13 |
ハイファイバイオ (エイチケー) リミテッド |
抗ガレクチン-9抗体およびその使用
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
CN111205371B
(zh)
*
|
2020-01-22 |
2022-03-29 |
北京吉尔麦迪生物医药科技有限公司 |
一种抗淋巴细胞激活基因3的抗体及应用
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
US11753403B2
(en)
|
2020-03-03 |
2023-09-12 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
AU2021240068A1
(en)
|
2020-03-19 |
2022-09-08 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
BR112022018678A2
(pt)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Degradadores de mdm2 e usos dos mesmos
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
US20230159573A1
(en)
|
2020-03-26 |
2023-05-25 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
EP4157875A1
(en)
|
2020-06-02 |
2023-04-05 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2022008519A1
(en)
|
2020-07-07 |
2022-01-13 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
US20230233690A1
(en)
|
2020-07-10 |
2023-07-27 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
KR20230044480A
(ko)
|
2020-07-30 |
2023-04-04 |
카이메라 쎄라퓨틱스 인코포레이티드 |
돌연변이 림프종의 치료 방법
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2023001707A
(es)
|
2020-08-10 |
2023-05-04 |
Shanghai Xunbaihui Biotechnology Co Ltd |
Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
|
KR20230050389A
(ko)
|
2020-08-13 |
2023-04-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-2를 관심 표적 세포로 재지시하는 방법
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
BR112023003427A2
(pt)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para carcinoma hepatocelular
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023538955A
(ja)
|
2020-08-31 |
2023-09-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在シグネチャーおよび免疫療法
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2022120354A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255929A2
(en)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
EP4259149A1
(en)
|
2020-12-08 |
2023-10-18 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
CN114621344B
(zh)
*
|
2020-12-10 |
2022-08-30 |
北京东方百泰生物科技股份有限公司 |
一种抗lag-3单克隆抗体的纯化方法
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN116964050A
(zh)
|
2020-12-16 |
2023-10-27 |
戈萨默生物服务公司 |
可用作t细胞激活剂的化合物
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
CA3201348A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Antibody compositions and methods of use thereof
|
WO2022148979A1
(en)
|
2021-01-11 |
2022-07-14 |
Bicycletx Limited |
Methods for treating cancer
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
BR112023015590A2
(pt)
|
2021-02-02 |
2023-10-17 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 e usos dos mesmos
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
CA3207380A1
(en)
|
2021-02-15 |
2022-08-18 |
Haojing RONG |
Irak4 degraders and uses thereof
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
AR125298A1
(es)
|
2021-04-06 |
2023-07-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー, インコーポレイテッド |
Mek阻害剤及びその使用
|
WO2022240741A1
(en)
|
2021-05-12 |
2022-11-17 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN117337288A
(zh)
|
2021-05-21 |
2024-01-02 |
艾库斯生物科学有限公司 |
Axl抑制剂化合物
|
TW202313602A
(zh)
|
2021-05-21 |
2023-04-01 |
美商阿克思生物科學有限公司 |
Axl化合物
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
TW202321237A
(zh)
|
2021-07-14 |
2023-06-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
TW202321238A
(zh)
|
2021-07-15 |
2023-06-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230150997A1
(en)
|
2021-08-25 |
2023-05-18 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023039089A1
(en)
|
2021-09-08 |
2023-03-16 |
Twentyeight-Seven, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
WO2023051621A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
中山康方生物医药有限公司 |
抗lag3抗体、药物组合物及用途
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023077046A1
(en)
|
2021-10-29 |
2023-05-04 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha and methods of use thereof
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
TW202342474A
(zh)
|
2022-02-14 |
2023-11-01 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
CN114874324B
(zh)
*
|
2022-05-13 |
2023-02-03 |
苏州旭光科星抗体生物科技有限公司 |
一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
US20240124490A1
(en)
|
2022-07-15 |
2024-04-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024059142A1
(en)
|
2022-09-14 |
2024-03-21 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
CN115819595B
(zh)
*
|
2023-01-03 |
2023-05-16 |
上海百英生物科技股份有限公司 |
一种抗lag3纳米抗体及其制备方法与应用
|